BMC Psychiatry (Nov 2021)

Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial

  • Martin P. Paulus,
  • Rayus Kuplicki,
  • Teresa A. Victor,
  • Hung-Wen Yeh,
  • Sahib S. Khalsa

DOI
https://doi.org/10.1186/s12888-021-03583-7
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Adherence to treatment, i.e. the extent to which a patient’s therapeutic engagement coincides with the prescribed treatment, is among the most important problems in mental health care. The current study investigated the influence of pairing an acute positive reinforcing dopaminergic/noradrenergic effect (methylphenidate, MPH) with a standard antidepressant on the rates of adherence to medication treatment. The primary objective of this study was to determine whether MPH + escitalopram resulted in higher rates of medication adherence relative to placebo + escitalopram. Methods Twenty participants with moderate to severe depression were 1–1 randomized to either (1) 5 mg MPH + 10 mg escitalopram or (2) placebo + 10 mg escitalopram with the possibility for a dose increase at 4 weeks. A Bayesian analysis was conducted to evaluate the outcomes. Results First, neither percent Pill count nor Medication Electronic Monitoring System adherence showed that MPH was superior to placebo. In fact, placebo showed slightly higher adherence rates on the primary (7.82% better than MPH) and secondary (7.07% better than MPH) outcomes. There was a less than 25% chance of MPH augmentation showing at least as good or better adherence than placebo. Second, both groups showed a significant effect of treatment on the QIDS-SR with a median effect of an 8.6-point score reduction. Third, neither subjective measures of adherence attitudes nor socio-demographic covariates had a significant influence on the primary or secondary outcome variables. Conclusions These data do not support the use of MPH to increase adherence to antidepressant medication in individuals with moderate to severe depression. ClinicalTrials.gov identifier NCT03388164 , registered on 01/02/2018.

Keywords